Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment
Evidence from a laboratory life-history trade-offs selection study
Abstract
Mass drug administration of praziquantel is the World Health Organization’s endorsed control strategy for schistosomiasis. A decade of annual treatments across sub-Saharan Africa has resulted in significant reductions of infection prevalence and intensity levels, although ‘hotspots’ remain. Repeated drug treatments place strong selective pressures on parasites, which may affect life-history traits that impact transmission dynamics. Understanding drug treatment responses and the evolution of such traits can help inform on how to minimise the risk of drug resistance developing, maximise sustainable control programme success, and improve diagnostic protocols.
This work arises from the Zoonoses and Emerging Livestock Systems (ZELS) programme.
Citation
Lamberton P, Faust C, Webster J (2017). Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study. Infectious Diseases of Poverty. 6(1): 110